Evidence from a population pharmacokinetics analysis for a major effect of CYP1A2 activity on inter- and intraindividual variations of clozapine clearance

被引:30
作者
Dailly, E
Urien, S
Chanut, E
Claudel, B
Guerra, N
Fernandez, C
Jolliet, P
Bourin, M
机构
[1] Hop Hotel Dieu, Fac Med, Pharmacol Lab, F-44035 Nantes 01, France
[2] Fac Med, Pharmacol Lab, Creteil, France
[3] Hop Paul Guiraud, Biol Lab, Villejuif, France
[4] Hop La Pitie Salpetriere, Psychiat Serv, Paris, France
[5] Hop La Pitie Salpetriere, Serv Pharm Toxicol, Paris, France
关键词
clozapine; cytochrome P450 1A2; therapeutic drug monitoring;
D O I
10.1016/S0278-5846(01)00320-7
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Interindividual variations of clozapine clearance could be related to individual CYP1A2 activity. A population approach was used to investigate clozapine pharmacokinetics of multiple doses of clozapine in patients. Clozapine plasma concentrations were obtained in 23 patients from therapeutic drug monitoring (83 samples). CYP1A2 activity was estimated by the norclozapine/clozapine plasma levels ratio and data were processed by a nonlinear mixed-effect modelling method. Different covariates (age, body weight, height, CYP1A2 activity, daily dose of clozapine) were tested but CYP1A2 activity was the single parameter that improved significantly the predictive model. The best fit was obtained by integration of a linear relationship between clozapine clearance and CYP1A2 activity. The findings suggest that (i) CYP1A2 activity is a major factor that determines clozapine clearance and (ii) the norclozapine/clozapine ratio could constitute a valuable measure of the CYP1A2 activity. This ratio can be simply determined in the context of therapeutic drug monitoring and could explain the inter- and intraindividual variation of clozapine plasma levels. (C) 2002 Elsevier Science Inc. All rights reserved.
引用
收藏
页码:699 / 703
页数:5
相关论文
共 16 条
[1]   CLOZAPINE DISPOSITION COVARIES WITH CYP1A2 ACTIVITY DETERMINED BY A CAFFEINE TEST [J].
BERTILSSON, L ;
CARRILLO, JA ;
DAHL, ML ;
LLERENA, A ;
ALM, C ;
BONDESSON, U ;
LINDSTROM, L ;
DELARUBIA, IR ;
RAMOS, S ;
BENITEZ, J .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1994, 38 (05) :471-473
[2]   Cytochrome P450 and therapeutic drug monitoring with respect to clozapine [J].
Buur-Rasmussen, B ;
Brosen, K .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 1999, 9 (06) :453-459
[3]   Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients [J].
Carrillo, JA ;
Herraiz, AG ;
Ramos, SI ;
Benítez, J .
JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1998, 18 (04) :311-316
[4]   CLINICAL PHARMACOKINETICS OF CLOZAPINE IN CHRONIC-SCHIZOPHRENIC PATIENTS [J].
CHENG, YF ;
LUNDBERG, T ;
BONDESSON, U ;
LINDSTROM, L ;
GABRIELSSON, J .
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 34 (05) :445-449
[5]   Stability and performance of a population pharmacokinetic model [J].
Ette, EI .
JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 37 (06) :486-495
[6]   Determination of clozapine and its major metabolites in human plasma and red blood cells by high-performance liquid chromatography with ultraviolet absorbance detection [J].
Guitton, C ;
Kinowski, JM ;
Aznar, R ;
Bressolle, F .
JOURNAL OF CHROMATOGRAPHY B, 1997, 690 (1-2) :211-222
[7]   Clozapine and metabolite concentrations during treatment of patients with chronic schizophrenia [J].
Guitton, C ;
Kinowski, JM ;
Abbar, M ;
Chabrand, P ;
Bressolle, F .
JOURNAL OF CLINICAL PHARMACOLOGY, 1999, 39 (07) :721-728
[8]   PHARMACOKINETICS AND PHARMACODYNAMICS OF CLOZAPINE [J].
JANN, MW ;
GRIMSLEY, SR ;
GRAY, EC ;
CHANG, WH .
CLINICAL PHARMACOKINETICS, 1993, 24 (02) :161-176
[9]   FLUVOXAMINE INHIBITION AND CARBAMAZEPINE INDUCTION OF THE METABOLISM OF CLOZAPINE - EVIDENCE FROM A THERAPEUTIC DRUG-MONITORING SERVICE [J].
JERLING, M ;
LINDSTROM, L ;
BONDESSON, U ;
BERTILSSON, L .
THERAPEUTIC DRUG MONITORING, 1994, 16 (04) :368-374
[10]   Population pharmacokinetics of clozapine evaluated with the nonparametric maximum likelihood method [J].
Jerling, M ;
Merle, Y ;
Mentre, F ;
Mallet, A .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1997, 44 (05) :447-453